Blog
RSS FeedPosted by Michael Wonder on 19 Jun 2026
Recommendations made by the PBAC – May 2026
19 June 2026 - Recommendations made by the PBAC in May 2026 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 09 Jun 2026
New progress toward public reimbursement of Skyclarys for people living with Friedreich ataxia in Quebec
8 June 2026 - Biogen is pleased to announce a positive outcome from the Institut national d'excellence en santé et en ...
Posted by Michael Wonder on 05 Jun 2026
First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer
4 June 2026 - The treatment uses a targeted therapy that seeks out a specific protein found on the surface of ...
Posted by Michael Wonder on 24 May 2026
Gazyva (obinutuzumab) receives positive reimbursement recommendation from Canada's Drug Agency (CDA-AMC) for adults with active lupus nephritis
22 May 2026 - Roche Canada is pleased to share that on 6 May 2026, Canada's Drug Agency recommended Gazyva ...
Posted by Michael Wonder on 18 May 2026
Qalsody: new data has allowed for a reassessment by the HAS
21 April 2026 - The drug Qalsody (tofersen) aims to slow the progression of a rare genetic form of ALS (amyotrophic ...
Posted by Michael Wonder on 15 May 2026
SMC - May 2026 decisions
11 May 2026 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 15 May 2026
Wegovy and Mounjaro for weight loss not funded
14 May 2026 - PHARMAC has assessed the application to fund Wegovy for weight loss and added it to our ...
Posted by Michael Wonder on 15 May 2026
Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer
14 May 2026 - Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer. ...
Posted by Michael Wonder on 08 May 2026
NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed
8 May 2026 - Around 530 people in England will benefit from access to the Duchenne muscular dystrophy treatment givinostat, following ...
Posted by Michael Wonder on 30 Apr 2026
First NICE recommended treatment for uncontrolled generalised myasthenia gravis
29 April 2026 - We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis whose ...
Posted by Michael Wonder on 25 Apr 2026
Recommendations made by the PBAC – March 2026
24 April 2026 - Recommendations made by the PBAC in March 2026 relating to the listing of medicines on the ...
Posted by Michael Wonder on 22 Apr 2026
New life-extending treatment given the green light for people with rare form of bile duct cancer
21 April 2026 - A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended ...
Posted by Michael Wonder on 19 Apr 2026
New take at home drug recommended for people with chronic lymphocytic leukaemia
17 April 2026 - NICE has recommended a new take at home tablet for some people with chronic lymphocytic leukaemia whose ...
Posted by Michael Wonder on 16 Apr 2026
‘Trojan horse’ treatment recommended for people with multiple myeloma
16 April 2026 - Around 1,600 people a year in England with multiple myeloma are set to benefit from a ...
Posted by Michael Wonder on 10 Apr 2026
Cemiplimab in cutaneous squamous cell carcinoma: no suitable data due to insufficient observation period
16 March 2026 - To rule out a recurrence, patients must be monitored for a sufficient period of time, even after ...